Faster global financial news!
GLP-1
-
Novo Nordisk's amylin analog drug CagriSema is expected to launch early next year, with new data showing it can reduce "food noise."
Novo Nordisk's amylin drug CagriSema is expected to launch early next year, with the standalone cagrilintide and high-dose CagriSema anticipated in 2028. New data released by Novo Nordisk this week sh
-
Analysis: Novo Nordisk stock 'too cheap to ignore' after 66%+ drop from 2024 high, despite Eli Lilly GLP-1 competition
The Motley Fool analysis suggests that after Novo Nordisk's stock declined over 66% from its 2024 high, traditional valuation metrics like price-to-sales (4x vs 5-year average 8.6x) and price-to-earni
-
Conexeu Sciences CEO Miles Harrison Highlights Tissue Regeneration Tech for GLP-1 Related Volume Loss, Eyes Early 2027 FDA Submission
During a fireside chat, Conexeu Sciences Inc. (Nasdaq: CNXU) CEO Miles Harrison discussed the company's preclinical-stage tissue regeneration technology, which aims to address large-volume tissue rest
-
Novo Nordisk's amylin analog drug CagriSema is expected to launch early next year, with new data showing it can reduce "food noise."
Novo Nordisk's amylin drug CagriSema is expected to launch early next year, with the standalone cagrilintide and high-dose CagriSema anticipated in 2028. New data released by Novo Nordisk this week sh
-
Analysis: Novo Nordisk stock 'too cheap to ignore' after 66%+ drop from 2024 high, despite Eli Lilly GLP-1 competition
The Motley Fool analysis suggests that after Novo Nordisk's stock declined over 66% from its 2024 high, traditional valuation metrics like price-to-sales (4x vs 5-year average 8.6x) and price-to-earni
-
Conexeu Sciences CEO Miles Harrison Highlights Tissue Regeneration Tech for GLP-1 Related Volume Loss, Eyes Early 2027 FDA Submission
During a fireside chat, Conexeu Sciences Inc. (Nasdaq: CNXU) CEO Miles Harrison discussed the company's preclinical-stage tissue regeneration technology, which aims to address large-volume tissue rest
- No data
GLP-1
24H Trending
-
1
CME Launches 24/7 Crypto Futures Trading: Market Impact and Mechanism Analysis
-
2
OKX USDT Perpetual Contract Index Price Calculation Rules Explained
-
3
Quant Network (QNT) Token Analysis: Interoperability, Applications, and Market Outlook
-
4
Wrapped Cardano (WADA) Token Analysis: Value, Interoperability, and Investment Considerations
-
5
Analysis of Major Global Cryptocurrency Exchanges and Market Trends
-
6
DBEX Trading Platform Risk Alert and Overview of Mainstream Centralized Exchanges
-
7
Bitcoin, Gold, and Stocks: A Comparison of Risks, Returns, and Use Cases
-
8
NFXC Coin Status Analysis: Project Ecosystem, Market Performance, and Risk Considerations
-
9
What is HKBY coin? Trading Activity and Risk Warning
-
10
What is MATE? An Analysis of the Asset, Project Positioning, and Current Status
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
